Spain-based drugmaker REIG JOFRE (BME: RJF) has signed a commercial agreement with LEO Pharma, a privately-held Danish firm specializing in medical dermatology and thrombosis.
The partnership aims to strengthen the promotion of Enstilar (calcipotriol/betamethasone dipropionate foam), LEO’s innovative product for mild to moderate psoriasis within the scope of primary care in Spain. It is hoped that this work will help extend the treatment’s reach, improving patient access and enhancing support for healthcare professionals.
Enstilar’s unique formulation significantly improves anti-psoriatic response and has been recognized by Spanish trade group Farmaindustria as an incremental innovation, thanks to its advanced foam-based pharmaceutical formulation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze